Cancer immunotherapy in context

Pyxis Oncology is developing antibody therapeutics to promote the body's immune response to cancer, based on new insights into the tumor microenvironment.

About Us

The tumor microenvironment represents a unique biological setting, different in many important ways from other sites of immune activity throughout the body. Through a deep understanding of the role of the tumor microenvironment in immune cell trafficking and activity, Pyxis Oncology has unlocked multiple new avenues to restore the potency of dysfunctional immune cells. Pyxis is developing a diverse pipeline of new antibodies to enhance the immune response against cancer, even in tumor types that historically have not responded well to cancer immunotherapies.

 
 
Our Science

Many tumors types are surrounded by a hostile microenvironment that prevents immune cells from entering the tumor core, making them extraordinarily difficult to treat. These 'cold' tumors require novel therapeutic approaches to interrupt the negative regulation of tumor cells and to promote increased immune cell infiltration and motility.  Simultaneously, for 'hot' tumors that do permit immune cell infiltration, the tumor microenvironment often inhibits normal immune cell functioning.

 

Pyxis has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors. This has led to the discovery of a novel array of positive and negative regulators of immune cell infiltration and functioning, paving the way for the development of novel antibody-based immunotherapies.

 

Management Team and Board

Ronald-Herbst-Pyxis_edited.png

Chief Scientific Officer

Shaan Gandhi - Pyxis Oncology

Co-founder & President

Scientific Advisory Board

Thomas Gajewski - Pyxis Oncology

Co-founder & SAB Chair

David-Steinberg-Pyxis.jpg

Founding CEO & Chairman

John-Flavin-Pyxis.jpg

Co-founder, Founding Chairman and Independent Director

 
Investors
leaps logo - Pyxis Oncology - antibody therapeutics - cancer immunotherapy
Agent Capital logo - Pyxis Oncology - antibody therapeutics - cancer immunotherapy
longwood logo - Pyxis Oncology - antibody therapeutics - cancer immunotherapy
Ipsen logo - Pyxis Oncology - antibody therapeutics - cancer immunotherapy
 
Join Us

Help us discover cures. Learn more about our open positions and apply today:

Scientist, Biology
Research Associate, Biology
 
News Release
December 11, 2019

Pyxis Oncology Appoints Lara Sullivan, M.D. as Chief Executive Officer and Director

News Release
October 16, 2019

 Pyxis Oncology Appoints Pharmaceutical Industry Veteran Ronald Herbst, PhD, as Chief Scientific Officer 

News Release
July 17, 2019

Pyxis Oncology Founded by

Longwood Fund with 

Financing Led by Bayer

News Article
July 17, 2019
Endpoints News

Bayer, Longwood back star researcher's deep dive into the tumor microenvironment for new I/O targets

News Article
July 17, 2019
BioCentury

Bayer-backed Pyxis debuts with $22M to pursue new immuno-oncology targets

 

75 Kneeland Street, 14th floor

Boston, MA 02111

  • Grey LinkedIn Icon
Send Us a Message

© 2019 Pyxis Oncology